Black Diamond Therapeutics (BDTX) Free Cash Flow: 2019-2021
Historic Free Cash Flow for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$24.4 million.
- Black Diamond Therapeutics' Free Cash Flow fell 53.49% to -$24.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$102.9 million, marking a year-over-year decrease of 96.71%. This contributed to the annual value of -$62.3 million for FY2024, which is 6.66% up from last year.
- Latest data reveals that Black Diamond Therapeutics reported Free Cash Flow of -$24.4 million as of Q4 2021, which was up 11.86% from -$27.7 million recorded in Q3 2021.
- Over the past 5 years, Black Diamond Therapeutics' Free Cash Flow peaked at -$5.0 million during Q2 2019, and registered a low of -$27.7 million during Q3 2021.
- Over the past 3 years, Black Diamond Therapeutics' median Free Cash Flow value was -$12.5 million (recorded in 2020), while the average stood at -$15.0 million.
- Data for Black Diamond Therapeutics' Free Cash Flow shows a maximum YoY crashed of 171.95% (in 2020) over the last 5 years.
- Quarterly analysis of 3 years shows Black Diamond Therapeutics' Free Cash Flow stood at -$7.5 million in 2019, then tumbled by 112.11% to -$15.9 million in 2020, then crashed by 53.49% to -$24.4 million in 2021.
- Its last three reported values are -$24.4 million in Q4 2021, -$27.7 million for Q3 2021, and -$26.0 million during Q2 2021.